Webcast ImageWebcast
Neos Therapeutics at the UBS Global Healthcare Conference (Live)
05/22/18 at 9:30 a.m. ET

Corporate Profile

Neos Therapeutics develops, manufactures, and commercializes innovative extended-release (XR) products using our proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms. We have three approved ADHD products, two of which use our ODT technology and one of which is an extended-release (ER) oral suspension. Our growing ADHD product portfolio puts Neos in a unique position to help meet the different needs of patients that struggle with ADHD.

News Releases